About Sompharmaceuticals
Sompharmaceuticals is a company based in Epalinges (Switzerland) founded in 2012 was acquired by Amryt Pharma in April 2016. Sompharmaceuticals has raised $851.87 thousand across 2 funding rounds from investors including Amryt Pharma. Sompharmaceuticals operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Epalinges, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$851.87 K (USD)
in 2 rounds
-
Latest Funding Round
$851.87 K (USD), Series A
Apr 29, 2014
- Investors
-
Employee Count
Not available
-
Acquired by
Amryt Pharma
(Apr 18, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Sompharmaceuticals
Sompharmaceuticals has successfully raised a total of $851.87K across 2 strategic funding rounds. The most recent funding activity was a Series A round of $851.87 thousand completed in April 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sompharmaceuticals
Sompharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Amryt Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for rare dermatological and orphan diseases are developed.
|
Locked | Locked | Locked |
Investor details for Sompharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sompharmaceuticals
Investment portfolio details for Sompharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sompharmaceuticals
Detailed financials for Sompharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sompharmaceuticals Comparisons
Peer comparison for Sompharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sompharmaceuticals
Sompharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapies for rare and orphan diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat rare genetic diseases
|
Detailed competitors of Sompharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sompharmaceuticals
Complete news archive for Sompharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sompharmaceuticals
Sompharmaceuticals was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Sompharmaceuticals is headquartered in Epalinges, Switzerland. It is registered at Epalinges, Vaud, Switzerland.
Sompharmaceuticals is a funded company, having raised a total of $851.87K across 2 funding rounds to date.
SomPharmaceuticals was founded in 2012 as a biopharmaceutical entity in Epalinges, Switzerland. Focus is placed on somatostatin analogue peptide medicines targeting rare neuroendocrine conditions, including orphan drug candidates for acromegaly and Cushings disease. Operations emphasize development for patient needs in these areas. As of May 13, 2016, the company has been operated as a subsidiary of Amryt Pharma.
Sompharmaceuticals's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Sompharmaceuticals has 1 investor. Key investors include Amryt Pharma.